Akoya to Report First Quarter 2021 Financial Results on May 18, 2021
Rhea-AI Summary
Akoya Biosciences (Nasdaq: AKYA) will release its first quarter 2021 financial results after market close on May 18, 2021. Management will discuss these results during a conference call scheduled for 5:00 p.m. ET. Investors can participate by calling (833) 562-0146 domestically or (661) 567-1226 internationally, using Conference ID: 7824008. A live and archived webcast will also be available on the Akoya website.
Akoya is known for its spatial biology solutions, including CODEX® and Phenoptics™ platforms, which allow researchers to explore cell interactions in health and disease.
Positive
- None.
Negative
- None.
News Market Reaction – AKYA
In the trading session that priced this news, AKYA gained 6.71%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MARLBOROUGH, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the first quarter of 2021 after the market close on Tuesday, May 18, 2021. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.
Investors interested in listening to the conference call may do so by dialing (833) 562-0146 for domestic callers or (661) 567-1226 for international callers, followed by Conference ID: 7824008. A live and archived webcast of the event will be available on the “Investors” section of the Akoya website at https://investors.akoyabio.com/.
About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. Akoya offers two distinct solutions, the CODEX® and Phenoptics™ platforms, to serve the diverse needs of researchers across discovery, translational and clinical research.
Investor Contact:
David Deuchler
Gilmartin Group LLC
investors@akoyabio.com
Media Contact:
Michelle Linn
Bioscribe, Inc.
774-696-3803
michelle@bioscribe.com